IART

Integra LifeSciences Holdings Corporation (IART) | Rumor.io

Integra LifeSciences Holdings

IART

Attention (50-day avg)0%

Attention rank (50-day avg)#3,957

Bullish sentiment (50-day avg)100%

Price to earnings ratio66.5

Market capitalization1.3B

Earnings per share-0.09

Dividend yield (TTM)—

Revenue (annual)1.6B

Net income (annual)-516.5M

Social

What share of all stock conversation is about IART?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 5

Integra LifeSciences Holdings Corporation ($IART) reported Q1 2026 revenues of $391.9M, a 2.4% increase, with adjusted net income of $41.6M ($0.54/share).
The company raised full-year EPS guidance to $2.40-$2.50 and reaffirmed revenue guidance of $1.662-$1.702B.
Integra LifeSciences appointed Stuart M. Essig as President & CEO, effective May 1, 2026, and Michael McBreen as Chief Commercial Officer.

Generated by AI

Sentiment

Of the messages about IART that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.52% +28.38
Bearish	—	—	—	4.48% -28.38

Oct 26

$IART missed EPS estimates by $0.02 and revenue estimates.
Integra LifeSciences Holdings Corporation ($IART) missed Estimize EPS and revenue consensus.
Zacks Investment Research downgraded $IART to a Hold rating.

Generated by AI

Topics

Of the messages about IART that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	42.61%
Technical Analysis	—	—	—	27.83%
Analysts	—	—	—	16.52%
Earnings	—	—	—	7.83%
Controversies	—	—	—	1.74%
Macro	—	—	—	3.48%

Earnings· Oct 26

Integra LifeSciences Holdings Corporation ($IART) reported Q3 2022 earnings of $0.86 EPS and $385.19M revenue, beating estimates by 13c and $4.53M, respectively.
The company's non-GAAP EPS of $0.86 beat the consensus by $0.14, while revenue of $385.19M exceeded the estimate by $6.87M.
Integra LifeSciences updated its FY22 guidance to $3.29-$3.33 EPS and revenue guidance to $1.551-$1.563 billion.

Analysts· Oct 28

Integra LifeSciences Holdings Corporation ($IART) has been assigned a $62.00 price target by Wells Fargo & Co analysts.
Oppenheimer analysts have given Integra LifeSciences Holdings Corporation ($IART) a $68.00 price target.
Royal Bank of Canada analysts have reiterated a $62.00 price target for Integra LifeSciences Holdings Corporation ($IART).

Announcements· May 6

Integra LifeSciences Holdings Corporation reported a net loss of $3.3m and EPS of $(0.04) for Q1 2024, with revenue of $368.9m, down 3.1% YoY.
The company updated its FY 2024 revenue guidance to $1.67b-$1.69b and acquired Acclarent, Inc.
Integra LifeSciences CEO Jan De Witte stated that the company is focused on executing key priorities, including enhancing manufacturing operations, advancing new product pipelines, and integrating the Acclarent business.

Technical Analysis· Apr 25

$IART broke previous high on massive volume, indicating strong buying pressure.
MACD/signal line crossover suggests a potential bullish signal for the asset.
$IART remains in a long-term bullish channel, supporting the idea of continued upward momentum.

Generated by AI

Community

Of the messages about IART, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	13.35%
Newcomers	—	—	—	86.65%

Regulars· May 23

Integra LifeSciences Holdings Corporation's stock price has declined 20.3% since the previous close, with a significant drop of 4% following a voluntary global recall of all products manufactured in Boston.
The company's Q2 guidance has been lowered, and an impairment charge has been reported, leading to a downgraded rating at Citi.
Integra LifeSciences is subject to investigation by Johnson Fistel, seeking remedies for investors after the stock drop, and its share price has decreased by 20.8%, hitting a new 52-week low.

Newcomers· May 5

Integra LifeSciences (IART) reported weaker-than-expected earnings and lowered its guidance, resulting in a nearly 30% stock drop.
The company's Q1 adjusted EPS of 41c missed the consensus estimate of 43c, and Q2 adjusted EPS is expected to be 40c-45c, below the consensus of 57c.
Integra LifeSciences lowered its FY25 adjusted EPS guidance to $2.19-$2.29, from $2.41-$2.51, citing a need to strengthen quality systems and drive operational excellence.

Generated by AI

News

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

19d agoYahoo! Finance Canada

Integra LifeSciences at Wells Fargo healthcare conference: recovery gains pace

20d agoInvesting.com

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, Septe

25d agoYahoo Finance

3 Cash-Producing Stocks That Fall Short

Detailed price information for Trupanion Inc (TRUP-Q) from The Globe and Mail including charting and trades.

27d agotheglobeandmail.com

Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)

27d agoSeeking Alpha

Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

1mo agoYahoo Finance

Also Discussed

Investors talking about IART also mention

#	Name	Attention
1	Fortrea Holdings Inc.FTRE	0%0
2	Vestis CorporationVSTS	0%new
3	Dianthus Therapeutics Inc.DNTH	0%0
4	Bruker CorpBRKR	0%0
5	Insight Enterprises, Inc.NSIT	0%0
6	Acadia Healthcare Company, Inc.ACHC	0%new
7	CareDx IncCDNA	0.01%+0.01
8	UroGen Pharma Ltd.URGN	0%new
9	Forte Biosciences, Inc.FBRX	0%new
10	Travere Therapeutics Inc.TVTX	0%0

Integra LifeSciences Holdings Corporation

Healthcare
Medical Devices

Integra LifeSciences Holdings Corporation is a medical technology company that develops, manufactures, and markets products used in neurosurgery, regenerative medicine, and surgical reconstruction. The company’s current business is organized around two main segments, Codman Specialty Surgical and Tissue Technologies, which support procedures in neurosurgery, neurocritical care, otolaryngology, wound repair, and tissue reconstruction. Its portfolio includes surgical instruments, dural repair products, cerebrospinal fluid management devices, cranial stabilization tools, and regenerative tissue technologies designed for complex wound and reconstructive care. Integra LifeSciences Holdings Corporation serves hospitals, surgery centers, and specialist clinicians across a range of medical disciplines, making it an important supplier in the healthcare equipment market. Headquartered in Princeton, New Jersey, the company focuses on providing clinically oriented solutions for procedures that require precision, reliability, and specialized surgical support.

Website

Location

1100 Campus Road

Princeton, NJ, 08540

United States

Social

What share of all stock conversation is about IART?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 5

Integra LifeSciences Holdings Corporation ($IART) reported Q1 2026 revenues of $391.9M, a 2.4% increase, with adjusted net income of $41.6M ($0.54/share).
The company raised full-year EPS guidance to $2.40-$2.50 and reaffirmed revenue guidance of $1.662-$1.702B.
Integra LifeSciences appointed Stuart M. Essig as President & CEO, effective May 1, 2026, and Michael McBreen as Chief Commercial Officer.

Generated by AI

Sentiment

Of the messages about IART that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.52% +28.38
Bearish	—	—	—	4.48% -28.38

Oct 26

$IART missed EPS estimates by $0.02 and revenue estimates.
Integra LifeSciences Holdings Corporation ($IART) missed Estimize EPS and revenue consensus.
Zacks Investment Research downgraded $IART to a Hold rating.

Generated by AI

Topics

Of the messages about IART that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	42.61%
Technical Analysis	—	—	—	27.83%
Analysts	—	—	—	16.52%
Earnings	—	—	—	7.83%
Controversies	—	—	—	1.74%
Macro	—	—	—	3.48%

Earnings· Oct 26

Integra LifeSciences Holdings Corporation ($IART) reported Q3 2022 earnings of $0.86 EPS and $385.19M revenue, beating estimates by 13c and $4.53M, respectively.
The company's non-GAAP EPS of $0.86 beat the consensus by $0.14, while revenue of $385.19M exceeded the estimate by $6.87M.
Integra LifeSciences updated its FY22 guidance to $3.29-$3.33 EPS and revenue guidance to $1.551-$1.563 billion.

Analysts· Oct 28

Integra LifeSciences Holdings Corporation ($IART) has been assigned a $62.00 price target by Wells Fargo & Co analysts.
Oppenheimer analysts have given Integra LifeSciences Holdings Corporation ($IART) a $68.00 price target.
Royal Bank of Canada analysts have reiterated a $62.00 price target for Integra LifeSciences Holdings Corporation ($IART).

Announcements· May 6

Integra LifeSciences Holdings Corporation reported a net loss of $3.3m and EPS of $(0.04) for Q1 2024, with revenue of $368.9m, down 3.1% YoY.
The company updated its FY 2024 revenue guidance to $1.67b-$1.69b and acquired Acclarent, Inc.
Integra LifeSciences CEO Jan De Witte stated that the company is focused on executing key priorities, including enhancing manufacturing operations, advancing new product pipelines, and integrating the Acclarent business.

Technical Analysis· Apr 25

$IART broke previous high on massive volume, indicating strong buying pressure.
MACD/signal line crossover suggests a potential bullish signal for the asset.
$IART remains in a long-term bullish channel, supporting the idea of continued upward momentum.

Generated by AI

Community

Of the messages about IART, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	13.35%
Newcomers	—	—	—	86.65%

Regulars· May 23

Integra LifeSciences Holdings Corporation's stock price has declined 20.3% since the previous close, with a significant drop of 4% following a voluntary global recall of all products manufactured in Boston.
The company's Q2 guidance has been lowered, and an impairment charge has been reported, leading to a downgraded rating at Citi.
Integra LifeSciences is subject to investigation by Johnson Fistel, seeking remedies for investors after the stock drop, and its share price has decreased by 20.8%, hitting a new 52-week low.

Newcomers· May 5

Integra LifeSciences (IART) reported weaker-than-expected earnings and lowered its guidance, resulting in a nearly 30% stock drop.
The company's Q1 adjusted EPS of 41c missed the consensus estimate of 43c, and Q2 adjusted EPS is expected to be 40c-45c, below the consensus of 57c.
Integra LifeSciences lowered its FY25 adjusted EPS guidance to $2.19-$2.29, from $2.41-$2.51, citing a need to strengthen quality systems and drive operational excellence.

Generated by AI

Integra LifeSciences Holdings

Social

May 5

Oct 26

Earnings· Oct 26

Analysts· Oct 28

Announcements· May 6

Technical Analysis· Apr 25

Regulars· May 23

Newcomers· May 5

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences at Wells Fargo healthcare conference: recovery gains pace

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

3 Cash-Producing Stocks That Fall Short

Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)

Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?

Also Discussed

Integra LifeSciences Holdings Corporation

Company Information

Location

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences at Wells Fargo healthcare conference: recovery gains pace

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

3 Cash-Producing Stocks That Fall Short

Integra LifeSciences: Strong Q2 2026 Results Support Recovery Thesis (NASDAQ:IART)

Integra (IART) Down 1.6% Since Last Earnings Report: Can It Rebound?

Also Discussed

Social

May 5

Oct 26

Earnings· Oct 26

Analysts· Oct 28

Announcements· May 6

Technical Analysis· Apr 25

Regulars· May 23

Newcomers· May 5